Sustained long-term improvement of arterial endothelial function in heterozygous familial hypercholesterolemia patients treated with simvastatin

Atherosclerosis

Volumn 157, Issue 2, 2001, Pages 423-429

  Alonso, R ^a   Mata, P ^a   De Andres, R ^a   Villacastin, B P ^a   Martinez Gonzalez J ^b   Badimon, Lina ^b  

^a Hospital UniversitarioFundación Jiménez Díaz   (Spain)

^b INST D INVESTIGACIONS B   (Spain)

Author keywords

Familial hypercholesterolemia; Flow mediated dilatation; sE selectin; Simvastatin

Indexed keywords

ANTILIPEMIC AGENT; CHOLESTEROL; ENDOTHELIAL LEUKOCYTE ADHESION MOLECULE 1; GLYCERYL TRINITRATE; INTERLEUKIN 6; LOW DENSITY LIPOPROTEIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; SIMVASTATIN; TUMOR NECROSIS FACTOR ALPHA;

ADULT; ARTERY ENDOTHELIUM; ARTICLE; BRACHIAL ARTERY; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EXPOSURE; ENZYME LINKED IMMUNOSORBENT ASSAY; FAMILIAL HYPERCHOLESTEROLEMIA; FEMALE; HETEROZYGOSITY; HUMAN; LONG TERM EXPOSURE; MALE; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN BLOOD LEVEL; SMOOTH MUSCLE RELAXATION; TREATMENT OUTCOME; ULTRASOUND;

ADULT; ANTILIPEMIC AGENTS; BRACHIAL ARTERY; E-SELECTIN; ENDOTHELIUM, VASCULAR; FEMALE; HETEROZYGOTE; HUMANS; HYPERLIPOPROTEINEMIA TYPE II; INTERLEUKIN-6; LIPIDS; MALE; MIDDLE AGED; SIMVASTATIN; TIME FACTORS; TREATMENT OUTCOME; TUMOR NECROSIS FACTOR-ALPHA; VASODILATION;

EID: 0034895788     PISSN: 00219150     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0021-9150(00)00733-4     Document Type: Article

References (39)

1. Development of coronary heart disease in familial hypercholesterolemia
2. Mortality in treated heterozygous familial hypercholesterolemia: Implications for clinical management
3. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: The Scandinavian Simvastatin Survival Group (4S)
4. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia
5. For the cholesterol and recurrent eqavents trial. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels
6. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels
7. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels
8. Impaired coronary blood flow response to acetylcoline in patients with coronary risk factors and proximal atherosclerotic lesions
9. Coronary vasomotor response to acetylcoline relates to risk factors for coronary artery disease
10. Non invasive detection of endothelial dysfunction in children and adults at risk of atherosclerosis
11. The role of nitric oxide in endothelium-dependent vasodilatation of hypercholesterolemic patients
12. Reduction in serum cholesterol with pravastatin improves endothelium-dependent coronary vasomotion in patients with hypercholesterolemia
13. Beneficial effects of cholesterol-lowering therapy on the coronary endothelium in patients with coronary artery disease
14. Vascular function in the forearm of hypercholesterolemic patients off and on lipid-lowering medication
15. Simvastatin, an HMG-coenzime A reductase inhibitor, improves endothelial function within 1 month
16. Single LDL apheresis improves endothelium-dependent vasodilatation in hypercholesterolemic humans
17. Levels of soluble cell adhesion molecules in patients with dyslipidemia
18. Circulating adhesion molecules VCAM-1, ICAM-1, and E-selectin in carotid atherosclerosis and incident coronary heart disease cases. The atherosclerosis risk in communities (ARIC) study
19. Plasma concentration of soluble intercellular adhesion molecule 1 and risks of future myocardial infarction in apparently healthy men
20. Circulating endothelial cell/leukocyte adhesion molecules in atherosclerosis
21. New indices of ischemic heart disease and aging: Studies on the serum levels of soluble intercellular adhesion molecule-1 (ICAM-1) and soluble vascular cell adhesion molecule-1 (VCAM-1) in patients with hypercholesterolemia and ischemic heart disease
22. Plasma cholesterol regulates soluble cell adhesion molecule expression in familial hypercholesterolemia
23. Neovascular expression of E-selectin, intracellular adhesion molecule-1, and vascular cell adhesion molecule-1 in human atherosclerosis and their relationship to intimal leukocyte content
24. Circulating adhesion molecules in disease
25. Soluble E-selectin is not a marker of unstable coronary plaque in serum of patients with ischemic heart disease
26. Diagnosing heterozygous familial hypercholesterolemia using new practical criteria validated by molecular genetics
27. Correlation between flow-mediated vasodilatation of the brachial artery and intima-media thickness in the carotid artery in men
28. Statins do more than just lower cholesterol
29. Antiatherothrombotic properties of statins. Implication for cardiovascular event reduction
30. Effects of atorvastatin monotherapy and simvastatin plus cholestyramine on arterial function in patients with severe primary hypercholesterolemia
31. The role of endothelial cell adhesion molecules in the development of atherosclerosis
32. Inflammation, obesity, stress and coronary heart disease: Is interleukin-6 the link?
33. Cholesterol reduction rapidly improves endothelial function after acute coronary syndromes: The RECIFE (reduction of cholesterol in ischemia and function of the endothelium) trial
34. Pravastatin has cholesterol-lowering independent effects on the artery wall of atherosclerotic monkeys
35. Upregulation of endothelial nitric oxide synthase by HMG-CoA reductase inhibitors
36. Downregulation of endothelial nitric oxide synthase produced by low density lipoproteins is blocked by HMG-CoA reductase inhibition
37. The role of neutrophils in myocardial ischemia-reperfusion injury
38. Prognostic impact of coronary vasodilator function on adverse long-term outcome of coronary heart disease